Ikarian Capital, LLC Cabaletta Bio, Inc. Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.21 - $23.36 $2.64 Million - $5.06 Million	216,620 New	216,620 $4.92 Million
Q4 2022 Feb 14, 2023	SELL	$0.64 - $9.3 $88,535 - $1.29 Million	-138,337 Reduced 82.04%	30,286 $280,000
Q3 2022 Nov 14, 2022	SELL	$0.63 - $2.05 $488,759 - $1.59 Million	-775,808 Reduced 82.15%	168,623 $109,000
Q2 2022 Aug 12, 2022	SELL	$0.99 - $2.11 $74,882 - $159,598	-75,639 Reduced 7.42%	944,431 $1 Million
Q1 2022 May 13, 2022	BUY	$1.68 - $3.92 $83,448 - $194,714	49,672 Added 5.12%	1,020,070 $2.07 Million
Q4 2021 Feb 14, 2022	SELL	$3.36 - $14.64 $730,800 - $3.18 Million	-217,500 Reduced 18.31%	970,398 $3.68 Million
Q3 2021 Nov 15, 2021	BUY	$7.0 - $12.5 $1.69 Million - $3.01 Million	240,770 Added 25.42%	1,187,898 $14.4 Million
Q2 2021 Aug 16, 2021	BUY	$7.2 - $11.73 $4.02 Million - $6.54 Million	557,744 Added 143.24%	947,128 $8.15 Million
Q1 2021 May 17, 2021	BUY	$10.39 - $14.53 $4.05 Million - $5.66 Million	389,384 New	389,384 $4.32 Million

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.